Arno Belpaire

Dr. Arno Belpaire

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 September 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
RSReinhart Speeckaert
Reinhart Speeckaert
ECElise Van Caelenberg
Elise Van Caelenberg
ABArno Belpaire
Arno Belpaire
Marijn M. SpeeckaertMarijn M. Speeckaert
Marijn M. Speeckaert
NGNanja Van Geel
Nanja Van Geel
Recent advances in vitiligo have provided promising treatment options, particularly through understanding the immune-mediated mechanisms leading to depigmentation. The inflammatory components in both vitiligo (non-segmental) and segmental vitiligo have similarities. Both are believed to result from an immune-based destruction of melanocytes by anti-melanocyte-specific cytotoxic T cells. The JAK-STAT pathway is activated with IFN-γ as the crucial cytokine and Th1-associated chemokines such as CXCL9 and CXCL10 recruit immune cells towards vitiligo skin. Nonetheless, clear differences are also present, such as the localized nature of segmental vitiligo, likely due to somatic mosaicism and increased presence of poliosis. The differing prevalence of poliosis suggests that the follicular immune privilege, which is known to involve immune checkpoints, may be more important in vitiligo (non-segmental). Immunomodulatory therapies, especially those targeting the JAK-IFNγ pathway, are currently at the forefront, offering effective inhibition of melanocyte destruction by cytotoxic T cells. Although Janus Kinase (JAK) inhibitors demonstrate high repigmentation rates, optimal results can take several months to years. The influence of environmental UV exposure on repigmentation in patients receiving immunomodulating drugs remains largely underexplored. Nonetheless, the combined effect of phototherapy with JAK inhibitors is impressive and suggests a targeted immune-based treatment may still require additional stimulation of melanocytes for repigmentation. Identifying alternative melanocyte stimulants beyond UV light remains crucial for the future management of vitiligo.

7 April 2022 in Pigment Cell & Melanoma Research
Verified
Journal Article
Closed access
RSReinhart Speeckaert
Reinhart Speeckaert
ABArno Belpaire
Arno Belpaire
MSMarijn Speeckaert
Marijn Speeckaert
NGNanja Van Geel
Nanja Van Geel

1 January 2024 in Immune Network
Verified
Journal Article
Open access
PDF file
RSReinhart Speeckaert
Reinhart Speeckaert
ABArno Belpaire
Arno Belpaire
JLjo l LW lambert
jo l LW lambert
Marijn M. SpeeckaertMarijn M. Speeckaert
Marijn M. Speeckaert
NGNanja Van Geel
Nanja Van Geel
Speeckaert R, et al. Immune Netw. 2024 Aug;24(5):e33. https://doi.org/10.4110/in.2024.24.e33

Verified
Journal Article
Open access
PDF file
RSReinhart Speeckaert
Reinhart Speeckaert
ABArno Belpaire
Arno Belpaire
Sandrine HerbeletSandrine Herbelet
Sandrine Herbelet
Marijn M. SpeeckaertMarijn M. Speeckaert
Marijn M. Speeckaert
NGNanja Van Geel
Nanja Van Geel
Background: Clinician-reported outcome measures (ClinROMs) are frequently used in clinical trials and daily practice to evaluate the disease status and evolution of skin disorders. The minimal important difference (MID) represents the smallest difference that decreases the disease impact enough to make a treatment change worthwhile for patients. As no clear guidance exists on the preferred method to calculate MIDs for ClinROMs, we evaluated how the published values for different skin disorders should be interpreted. Methods: A systematic search was performed for MIDs of ClinROMs that focus on skin disorders and/or symptoms. The results of the questions in the credibility instrument for MIDs of Devji et al., 2020 were analyzed to gain insights into the meaning of these MIDs. Results: 29 MIDs were identified. The most common skin diseases were atopic dermatitis/eczema, followed by bullous disorders and psoriasis. A minimal important difference from the patients’ perspective was determined in 31% of the cases. However, in 41.4% of the cases, it concerned a substantial rather than a minimal difference in disease severity rated by physicians. Over half (55.1%) of the studies contained an inadequate number of patients (n < 150). MID values increased substantially in patients with severe compared to mild disease. Conclusions: MIDs of ClinROMs for skin disorders should be carefully interpreted due to the substantial differences in methodology between the studies. There is an urgent need for a consensus method to report reliable MIDs. Otherwise, this lack of uniformity could not only affect the design and conclusion of clinical trials but also skew treatment decisions.

7 March 2025 in Journal of Translational Autoimmunity
Verified
Journal Article
Open access
ABArno Belpaire
Arno Belpaire
ADAnnelies Demeyer
Annelies Demeyer
ECElise Van Caelenberg
Elise Van Caelenberg
NGNanja Van Geel
Nanja Van Geel
RSReinhart Speeckaert
Reinhart Speeckaert
Despite significant progress in the treatment of alopecia areata (AA), many aspects of its immune-based pathogenesis remain unexplored. IFN-γ, primarily produced by CD8+ T cells and NK cells, is considered central to AA pathogenesis. However, the complex immune signaling network contributes to therapeutic resistance and frequent disease flares after treatment discontinuation. The aryl hydrocarbon receptor (AhR) pathway, upregulated by IFN-γ, modulates Th17 responses, but its inhibitory effects on IFN-γ remain unclear. Although IL-17 levels are elevated in AA, clinical trials indicate that IL-17A inhibitors are ineffective. AhR expression is known to induce immune checkpoints (ICPs) such as PD-1, suggesting a potential role as a negative feedback mechanism. This study investigated AhR expression in lymphocytes from AA patients and its association with clinical and laboratory markers of disease activity. AhR expression was significantly reduced in CD4, CD8, Th1, and Th17 lymphocytes in AA patients compared to healthy controls (p < 0.005), and it correlated inversely with SALTII scores (p < 0.05). ROC analysis showed that AhR levels in CD8 cells could differentiate mild AA from healthy controls with a sensitivity of 82.35 % and specificity of 86.84 %, suggesting potential diagnostic utility. Lower AhR levels were associated with increased IFN-γ+ lymphocytes and decreased IL-17+ immune cells. Interestingly, immune profiles differed between atopic and non-atopic patients: in severe AA, higher AhR expression was linked to increased sPD-1 concentrations, whereas in limited AA, AhR failed to upregulate any investigated ICP. These findings highlight the significant downregulation of the AhR pathway in AA and suggest its potential as a therapeutic target. Future research should explore the development of AhR agonists or antagonists to modulate immune responses in AA.

13 August 2025 in Journal of Investigative Dermatology
Verified
Journal Article
Open access
ABArno Belpaire
Arno Belpaire
ADAnnelies Demeyer
Annelies Demeyer
DBDanique Berrevoet
Danique Berrevoet
FNFilip Van Nieuwerburgh
Filip Van Nieuwerburgh
ECElise Van Caelenberg
Elise Van Caelenberg
RSReinhart Speeckaert
Reinhart Speeckaert
The kynurenine-aryl hydrocarbon receptor (AhR) axis restrains cytotoxic T-cell activity by tempering IFN-γ release and sustaining immune checkpoint expression, yet its status in vitiligo remains undefined. We profiled AhR expression in circulating T cells, quantified serum tryptophan and kynurenine, and assessed intracellular IFN-γ/IL-17A with soluble checkpoint molecules in 186 patients with nonsegmental vitiligo and 56 matched controls. Patients with vitiligo showed significantly reduced AhR expression in CD8+ T cells (P = .003) and a higher kynurenine/tryptophan ratio in active than in stable disease (P = .048). Low AhR expression in CD8+ T cells correlated inversely with IFN-γ-producing CD8+ cells (r = -0.376; P < .001), this correlation being stronger in active disease (r = -0.561). AhR expression positively correlated with soluble BTLA, soluble PD-1, and soluble TIM-3 levels in PBMC supernatants from patients with vitiligo. Pharmacologic activation of AhR with tapinarof dose-dependently suppressed IFN-γ+ T-cell frequencies, achieving a 55% reduction at 1 μM and a 47% reduction at 3 μM compared with stimulated controls (P < .05). These data identify disrupted kynurenine-AhR signaling as a driver of enhanced IFN-γ production in vitiligo and point to the potential of AhR agonists as targeted therapies to restore immune homeostasis and prevent disease activity in vitiligo.